Yuchong Peng
Jiangsu University(CN)Guangdong Pharmaceutical University(CN)First Affiliated Hospital of Guangdong Pharmaceutical University(CN)Yixing Tumor Hospital(CN)Yixing People's Hospital(CN)First People's Hospital of Chongqing(CN)Chongqing Medical University(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Ubiquitin and proteasome pathways, Prostate Cancer Treatment and Research, Gut microbiota and health, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells(2017)127 cited
- → PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells(2018)123 cited
- → Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma(2014)85 cited
- → UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications(2021)76 cited
- → Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition(2018)62 cited
- → FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness